Real-world experience of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma.
about
Afatinib in advanced NSCLC: a profile of its use.Prognostic factors of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma: a real-world, large cohort study.Preventing and treating brain metastases with three first-line EGFR-tyrosine kinase inhibitors in patients with EGFR mutation-positive advanced non-small cell lung cancer
P2860
Real-world experience of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh-hant
name
Real-world experience of afati ...... -positive lung adenocarcinoma.
@en
Real-world experience of afati ...... -positive lung adenocarcinoma.
@nl
type
label
Real-world experience of afati ...... -positive lung adenocarcinoma.
@en
Real-world experience of afati ...... -positive lung adenocarcinoma.
@nl
prefLabel
Real-world experience of afati ...... -positive lung adenocarcinoma.
@en
Real-world experience of afati ...... -positive lung adenocarcinoma.
@nl
P2093
P2860
P50
P356
P1433
P1476
Real-world experience of afati ...... n-positive lung adenocarcinoma
@en
P2093
Jin-Yuan Shih
Li-Ta Keng
Min-Shu Hsieh
P2860
P304
90430-90443
P356
10.18632/ONCOTARGET.19563
P407
P577
2017-07-26T00:00:00Z